_id
691302d9ccc777a4e85d79c9
Ticker
IPHA
Name
Innate Pharma
Exchange
NASDAQ
Address
117, Avenue de Luminy, Marseille, France, 13009
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.innate-pharma.com
Description
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
Last Close
1.82
Volume
16631
Current Price
1.7853
Change
0.07
Last Updated
2026-01-04T15:20:53.942Z
Image
data:image/webp;base64,UklGRloBAABXRUJQVlA4IE4BAABQCACdASpAAEAAPtFiqk6oJaQiKhZpcQAaCWkACwTHAhAOU8z0ra0ygRhdEfSglNTxxeDPxM/eKDR6LCCmKfIpR869uB38xKlHBAAA/vZQtHwOK5z9IcabJGuHxOCety9gibvqHCuTgQlqs3jEkpJ+Qqm7Jv6yL7jXtw9RO8KjJPeZ4rxX8q2d/Rg1w7jY507gRtXFdTNgwX42BQ+F83DpDno70hDAE8wS6HS2pTa8L+RD5CVyvrQaPwdwzIP4h9f64Rb7N5TTCEAtIybAm1ImGb9N1DI/S6uHvwzW60YFa2Dk58t3gY7ERfaJ9XJjYpuCsPWzAoxsDNAd4m7Vjr1FC64VYKHqaiPOk1C1s3bmxN9Sg1aFNfSgKikIVUxzT6YNLyhLLoqUMS5jfpfkaCwYVn8xgJZ4JCwdDXgrD+ATAzNd1jOd0Y/qmLwgAAAA
Ipo Date
2019-10-17T00:00:00.000Z
Market Cap
173698448
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Rating
4
Target Price
5.154
Strong Buy
1
Buy
1
Hold
1
Sell
0
Strong Sell
0
Current Quarter
2025-06-30
Revenue
4860000
Cost Of Revenue
20520000
Gross Profit
-15660000
Operating Expenses
9767000
Operating Income
-25427000
Interest Expense
-
Pretax Income
-21344000
Net Income
-21344000
Eps
-0.2455112725665711
Dividends Per Share
-
Shares Outstanding
92179248
Income Tax Expense
-
EBITDA
-25061000
Operating Margin
-523.1893004115227
Total Other Income Expense Net
4083000
Cash
53704000
Short Term Investments
6323000
Receivables
363000
Inventories
-
Total Current Assets
64977999
Property Plant Equipment
4955000
Total Assets
92937000
Payables
4551000
Short Term Debt
8934000
Long Term Debt
-
Total Liabilities
87793000
Equity
5144000
Bs_currency_symbol
EUR
Depreciation
707000
Change In Working Capital
-9959000
Cash From Operations
-31164000
Capital Expenditures
58000
Cash From Investing
6974000
Cash From Financing
10476000
Net Change In Cash
53704000
Cf_currency_symbol
-
PE
-
PB
30.17273093089036
ROE
-414.9300155520995
ROA
-22.966095311877936
FCF
-31222000
Fcf Percent
-6.424279835390947
Piotroski FScore
0
Health Score
8
Deep Value Investing Score
3
Defensive Investing Score
5.5
Dividend Investing Score
1.5
Economic Moat Investing Score
4.3
Garp Investing Score
3
Growth Investing Score
3
Momentum Investing Score
5.5
Net Net Investing Score
1.5
Quality Investing Score
1.5
Value Investing Score
2
Quarters > 0 > quarter
2025-06-30
Quarters > 0 > income Statement > revenue
4860000
Quarters > 0 > income Statement > cost Of Revenue
20520000
Quarters > 0 > income Statement > gross Profit
-15660000
Quarters > 0 > income Statement > operating Expenses
9767000
Quarters > 0 > income Statement > operating Income
-25427000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-21344000
Quarters > 0 > income Statement > net Income
-21344000
Quarters > 0 > income Statement > eps
-0.2455112725665711
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
86936945
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-25061000
Quarters > 0 > income Statement > operating Margin
-523.1893004115227
Quarters > 0 > income Statement > total Other Income Expense Net
4083000
Quarters > 0 > income Statement > currency_symbol
-
Quarters > 0 > balance Sheet > cash
53704000
Quarters > 0 > balance Sheet > short Term Investments
6323000
Quarters > 0 > balance Sheet > receivables
363000
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
64977999
Quarters > 0 > balance Sheet > property Plant Equipment
4955000
Quarters > 0 > balance Sheet > total Assets
92937000
Quarters > 0 > balance Sheet > payables
4551000
Quarters > 0 > balance Sheet > short Term Debt
8934000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
87793000
Quarters > 0 > balance Sheet > equity
5144000
Quarters > 0 > balance Sheet > currency_symbol
EUR
Quarters > 0 > cash Flow > net Income
-21344000
Quarters > 0 > cash Flow > depreciation
707000
Quarters > 0 > cash Flow > change In Working Capital
-9959000
Quarters > 0 > cash Flow > cash From Operations
-31164000
Quarters > 0 > cash Flow > capital Expenditures
58000
Quarters > 0 > cash Flow > cash From Investing
6974000
Quarters > 0 > cash Flow > cash From Financing
10476000
Quarters > 0 > cash Flow > net Change In Cash
53704000
Quarters > 0 > cash Flow > currency_symbol
-
Quarters > 0 > ratios > PE
-0.2455112725665711
Quarters > 0 > ratios > PB
30.17273093089036
Quarters > 0 > ratios > ROE
-414.9300155520995
Quarters > 0 > ratios > ROA
-22.966095311877936
Quarters > 0 > ratios > FCF
-31222000
Quarters > 0 > ratios > Piotroski FScore
0
Quarters > 0 > ratios > fcf Percent
-6.424279835390947
Quarters > 0 > health Score
8
Quarters > 1 > quarter
2025-03-31
Quarters > 1 > income Statement > revenue
276000
Quarters > 1 > income Statement > cost Of Revenue
-29076000
Quarters > 1 > income Statement > gross Profit
29352000
Quarters > 1 > income Statement > operating Expenses
54614000
Quarters > 1 > income Statement > operating Income
-25262000
Quarters > 1 > income Statement > interest Expense
34000
Quarters > 1 > income Statement > pretax Income
-24707000
Quarters > 1 > income Statement > net Income
-24707000
Quarters > 1 > income Statement > eps
-0.3048289986675221
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
81052000
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-21348000
Quarters > 1 > income Statement > operating Margin
-9152.898550724638
Quarters > 1 > income Statement > total Other Income Expense Net
555000
Quarters > 1 > income Statement > currency_symbol
-
Quarters > 1 > balance Sheet > cash
66396000
Quarters > 1 > balance Sheet > short Term Investments
14374000
Quarters > 1 > balance Sheet > receivables
1643000
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
85742000
Quarters > 1 > balance Sheet > property Plant Equipment
5133000
Quarters > 1 > balance Sheet > total Assets
111059000
Quarters > 1 > balance Sheet > payables
7923000
Quarters > 1 > balance Sheet > short Term Debt
8709000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
102225000
Quarters > 1 > balance Sheet > equity
8834000
Quarters > 1 > balance Sheet > currency_symbol
-
Quarters > 1 > cash Flow > net Income
-24707000
Quarters > 1 > cash Flow > depreciation
852000
Quarters > 1 > cash Flow > change In Working Capital
7852000
Quarters > 1 > cash Flow > cash From Operations
-9932000
Quarters > 1 > cash Flow > capital Expenditures
108000
Quarters > 1 > cash Flow > cash From Investing
8268000
Quarters > 1 > cash Flow > cash From Financing
-1681000
Quarters > 1 > cash Flow > net Change In Cash
-3594000
Quarters > 1 > cash Flow > currency_symbol
-
Quarters > 1 > ratios > PE
-0.3048289986675221
Quarters > 1 > ratios > PB
16.38013760470908
Quarters > 1 > ratios > ROE
-279.6807788091465
Quarters > 1 > ratios > ROA
-22.246733718113795
Quarters > 1 > ratios > FCF
-10040000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-36.3768115942029
Quarters > 1 > health Score
9
Quarters > 2 > quarter
2024-06-30
Quarters > 2 > income Statement > revenue
12345000
Quarters > 2 > income Statement > cost Of Revenue
29076000
Quarters > 2 > income Statement > gross Profit
-16731000
Quarters > 2 > income Statement > operating Expenses
9582000
Quarters > 2 > income Statement > operating Income
-26313000
Quarters > 2 > income Statement > interest Expense
600000
Quarters > 2 > income Statement > pretax Income
-24764000
Quarters > 2 > income Statement > net Income
-24764000
Quarters > 2 > income Statement > eps
-0.30621088891312187
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
80872369
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-25563000
Quarters > 2 > income Statement > operating Margin
-213.14702308626977
Quarters > 2 > income Statement > total Other Income Expense Net
1549000
Quarters > 2 > income Statement > currency_symbol
-
Quarters > 2 > balance Sheet > cash
69990000
Quarters > 2 > balance Sheet > short Term Investments
21809000
Quarters > 2 > balance Sheet > receivables
393000
Quarters > 2 > balance Sheet > inventories
3009000
Quarters > 2 > balance Sheet > total Current Assets
111594000
Quarters > 2 > balance Sheet > property Plant Equipment
5748000
Quarters > 2 > balance Sheet > total Assets
151497000
Quarters > 2 > balance Sheet > payables
8751000
Quarters > 2 > balance Sheet > short Term Debt
8929000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
122701000
Quarters > 2 > balance Sheet > equity
28796000
Quarters > 2 > balance Sheet > currency_symbol
EUR
Quarters > 2 > cash Flow > net Income
-24764000
Quarters > 2 > cash Flow > depreciation
1142000
Quarters > 2 > cash Flow > change In Working Capital
31310000
Quarters > 2 > cash Flow > cash From Operations
3036000
Quarters > 2 > cash Flow > capital Expenditures
283000
Quarters > 2 > cash Flow > cash From Investing
932000
Quarters > 2 > cash Flow > cash From Financing
-4327000
Quarters > 2 > cash Flow > net Change In Cash
69990000
Quarters > 2 > cash Flow > currency_symbol
-
Quarters > 2 > ratios > PE
-0.30621088891312187
Quarters > 2 > ratios > PB
5.013940838161551
Quarters > 2 > ratios > ROE
-85.9980552854563
Quarters > 2 > ratios > ROA
-16.34619827455329
Quarters > 2 > ratios > FCF
2753000
Quarters > 2 > ratios > Piotroski FScore
2
Quarters > 2 > ratios > fcf Percent
0.22300526528959091
Quarters > 2 > health Score
31
Quarters > 3 > quarter
2024-03-31
Quarters > 3 > income Statement > revenue
16557000
Quarters > 3 > income Statement > cost Of Revenue
24569000
Quarters > 3 > income Statement > gross Profit
-3126000
Quarters > 3 > income Statement > operating Expenses
9145000
Quarters > 3 > income Statement > operating Income
-7416000
Quarters > 3 > income Statement > interest Expense
3022000
Quarters > 3 > income Statement > pretax Income
-4434000
Quarters > 3 > income Statement > net Income
-9288000
Quarters > 3 > income Statement > eps
-0.11525479767019028
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
80586667
Quarters > 3 > income Statement > income Tax Expense
-9750000
Quarters > 3 > income Statement > EBITDA
-10396000
Quarters > 3 > income Statement > operating Margin
-44.79072295705744
Quarters > 3 > income Statement > total Other Income Expense Net
2982000
Quarters > 3 > income Statement > currency_symbol
-
Quarters > 3 > balance Sheet > cash
70605000
Quarters > 3 > balance Sheet > short Term Investments
21851000
Quarters > 3 > balance Sheet > receivables
46489000
Quarters > 3 > balance Sheet > inventories
3009000
Quarters > 3 > balance Sheet > total Current Assets
148012000
Quarters > 3 > balance Sheet > property Plant Equipment
6322000
Quarters > 3 > balance Sheet > total Assets
175187000
Quarters > 3 > balance Sheet > payables
8561000
Quarters > 3 > balance Sheet > short Term Debt
8936000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
123286000
Quarters > 3 > balance Sheet > equity
51901000
Quarters > 3 > balance Sheet > currency_symbol
-
Quarters > 3 > cash Flow > net Income
-9288000
Quarters > 3 > cash Flow > depreciation
1446000
Quarters > 3 > cash Flow > change In Working Capital
-13047000
Quarters > 3 > cash Flow > cash From Operations
-21093000
Quarters > 3 > cash Flow > capital Expenditures
42000
Quarters > 3 > cash Flow > cash From Investing
20877000
Quarters > 3 > cash Flow > cash From Financing
-720000
Quarters > 3 > cash Flow > net Change In Cash
-809000
Quarters > 3 > cash Flow > currency_symbol
-
Quarters > 3 > ratios > PE
-0.11525479767019028
Quarters > 3 > ratios > PB
2.772034769948556
Quarters > 3 > ratios > ROE
-17.895608947804472
Quarters > 3 > ratios > ROA
-5.301763258689286
Quarters > 3 > ratios > FCF
-21135000
Quarters > 3 > ratios > Piotroski FScore
0
Quarters > 3 > ratios > fcf Percent
-1.2764993658271426
Quarters > 3 > health Score
20
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
12621000
Annuals > 0 > income Statement > cost Of Revenue
51980000
Annuals > 0 > income Statement > gross Profit
12621000
Annuals > 0 > income Statement > operating Expenses
64196000
Annuals > 0 > income Statement > operating Income
-51575000
Annuals > 0 > income Statement > interest Expense
566000
Annuals > 0 > income Statement > pretax Income
-49471000
Annuals > 0 > income Statement > net Income
-49471000
Annuals > 0 > income Statement > eps
-0.6103612495681785
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
81052000
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-46911000
Annuals > 0 > income Statement > operating Margin
-408.64432295380715
Annuals > 0 > income Statement > total Other Income Expense Net
2104000
Annuals > 0 > income Statement > currency_symbol
EUR
Annuals > 0 > balance Sheet > cash
66396000
Annuals > 0 > balance Sheet > short Term Investments
14374000
Annuals > 0 > balance Sheet > receivables
1643000
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
85742000
Annuals > 0 > balance Sheet > property Plant Equipment
5133000
Annuals > 0 > balance Sheet > total Assets
111059000
Annuals > 0 > balance Sheet > payables
7923000
Annuals > 0 > balance Sheet > short Term Debt
8709000
Annuals > 0 > balance Sheet > long Term Debt
22182000
Annuals > 0 > balance Sheet > total Liabilities
102225000
Annuals > 0 > balance Sheet > equity
8834000
Annuals > 0 > balance Sheet > currency_symbol
EUR
Annuals > 0 > cash Flow > net Income
-49471000
Annuals > 0 > cash Flow > depreciation
1994000
Annuals > 0 > cash Flow > change In Working Capital
39162000
Annuals > 0 > cash Flow > cash From Operations
-6896000
Annuals > 0 > cash Flow > capital Expenditures
391000
Annuals > 0 > cash Flow > cash From Investing
9200000
Annuals > 0 > cash Flow > cash From Financing
-6008000
Annuals > 0 > cash Flow > net Change In Cash
-4209000
Annuals > 0 > cash Flow > currency_symbol
EUR
Annuals > 0 > ratios > PE
-0.6103612495681785
Annuals > 0 > ratios > PB
16.69851030110935
Annuals > 0 > ratios > ROE
-560.0067919402309
Annuals > 0 > ratios > ROA
-44.544791507216885
Annuals > 0 > ratios > FCF
-7287000
Annuals > 0 > ratios > Piotroski FScore
1
Annuals > 0 > ratios > fcf Percent
-0.5773710482529119
Annuals > 0 > health Score
9
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
51901000
Annuals > 1 > income Statement > cost Of Revenue
56022000
Annuals > 1 > income Statement > gross Profit
5619000
Annuals > 1 > income Statement > operating Expenses
18288000
Annuals > 1 > income Statement > operating Income
-12669000
Annuals > 1 > income Statement > interest Expense
640000
Annuals > 1 > income Statement > pretax Income
-7570000
Annuals > 1 > income Statement > net Income
-7570000
Annuals > 1 > income Statement > eps
-0.09000000011889035
Annuals > 1 > income Statement > dividends Per Share
0
Annuals > 1 > income Statement > shares Outstanding
84111111
Annuals > 1 > income Statement > income Tax Expense
-9729000
Annuals > 1 > income Statement > EBITDA
-1839000
Annuals > 1 > income Statement > operating Margin
-24.409934297990404
Annuals > 1 > income Statement > total Other Income Expense Net
5099000
Annuals > 1 > income Statement > currency_symbol
EUR
Annuals > 1 > balance Sheet > cash
70605000
Annuals > 1 > balance Sheet > short Term Investments
21851000
Annuals > 1 > balance Sheet > receivables
46489000
Annuals > 1 > balance Sheet > inventories
-3374000
Annuals > 1 > balance Sheet > total Current Assets
148012000
Annuals > 1 > balance Sheet > property Plant Equipment
6322000
Annuals > 1 > balance Sheet > total Assets
175187000
Annuals > 1 > balance Sheet > payables
8561000
Annuals > 1 > balance Sheet > short Term Debt
8936000
Annuals > 1 > balance Sheet > long Term Debt
30607000
Annuals > 1 > balance Sheet > total Liabilities
132292000
Annuals > 1 > balance Sheet > equity
51901000
Annuals > 1 > balance Sheet > currency_symbol
EUR
Annuals > 1 > cash Flow > net Income
-7570000
Annuals > 1 > cash Flow > depreciation
5091000
Annuals > 1 > cash Flow > change In Working Capital
-32091000
Annuals > 1 > cash Flow > cash From Operations
-32558000
Annuals > 1 > cash Flow > capital Expenditures
2351000
Annuals > 1 > cash Flow > cash From Investing
20631000
Annuals > 1 > cash Flow > cash From Financing
-1966000
Annuals > 1 > cash Flow > net Change In Cash
-13620000
Annuals > 1 > cash Flow > currency_symbol
EUR
Annuals > 1 > ratios > PE
-0.09000000011889035
Annuals > 1 > ratios > PB
2.9495042873933066
Annuals > 1 > ratios > ROE
-14.585460781102483
Annuals > 1 > ratios > ROA
-4.32109688504284
Annuals > 1 > ratios > FCF
-34909000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-0.6726074642107088
Annuals > 1 > health Score
20
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
57674000
Annuals > 2 > income Statement > cost Of Revenue
51663000
Annuals > 2 > income Statement > gross Profit
6011000
Annuals > 2 > income Statement > operating Expenses
63436000
Annuals > 2 > income Statement > operating Income
-57425000
Annuals > 2 > income Statement > interest Expense
288000
Annuals > 2 > income Statement > pretax Income
-57972000
Annuals > 2 > income Statement > net Income
-58103000
Annuals > 2 > income Statement > eps
-0.7295721615464102
Annuals > 2 > income Statement > dividends Per Share
0
Annuals > 2 > income Statement > shares Outstanding
79639826
Annuals > 2 > income Statement > income Tax Expense
41131000
Annuals > 2 > income Statement > EBITDA
-12279000
Annuals > 2 > income Statement > operating Margin
-99.56826299545722
Annuals > 2 > income Statement > total Other Income Expense Net
-547000
Annuals > 2 > income Statement > currency_symbol
EUR
Annuals > 2 > balance Sheet > cash
84225000
Annuals > 2 > balance Sheet > short Term Investments
17260000
Annuals > 2 > balance Sheet > receivables
3141000
Annuals > 2 > balance Sheet > inventories
-2000
Annuals > 2 > balance Sheet > total Current Assets
139831000
Annuals > 2 > balance Sheet > property Plant Equipment
8542000
Annuals > 2 > balance Sheet > total Assets
207863000
Annuals > 2 > balance Sheet > payables
13656000
Annuals > 2 > balance Sheet > short Term Debt
2102000
Annuals > 2 > balance Sheet > long Term Debt
38929000
Annuals > 2 > balance Sheet > total Liabilities
153712000
Annuals > 2 > balance Sheet > equity
54151000
Annuals > 2 > balance Sheet > currency_symbol
EUR
Annuals > 2 > cash Flow > net Income
-58103000
Annuals > 2 > cash Flow > depreciation
45405000
Annuals > 2 > cash Flow > change In Working Capital
-12502000
Annuals > 2 > cash Flow > cash From Operations
-19154000
Annuals > 2 > cash Flow > capital Expenditures
1122000
Annuals > 2 > cash Flow > cash From Investing
1877000
Annuals > 2 > cash Flow > cash From Financing
-1828000
Annuals > 2 > cash Flow > net Change In Cash
-19531000
Annuals > 2 > cash Flow > currency_symbol
EUR
Annuals > 2 > ratios > PE
-0.7295721615464102
Annuals > 2 > ratios > PB
2.6766723295968684
Annuals > 2 > ratios > ROE
-107.29811083821166
Annuals > 2 > ratios > ROA
-27.95254566709804
Annuals > 2 > ratios > FCF
-20276000
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-0.35156222908069495
Annuals > 2 > health Score
20
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
12112000
Annuals > 3 > income Statement > cost Of Revenue
47004000
Annuals > 3 > income Statement > gross Profit
-22301000
Annuals > 3 > income Statement > operating Expenses
25524000
Annuals > 3 > income Statement > operating Income
-47825000
Annuals > 3 > income Statement > interest Expense
312000
Annuals > 3 > income Statement > pretax Income
-45478000
Annuals > 3 > income Statement > net Income
-52809000
Annuals > 3 > income Statement > eps
-0.6639081708981022
Annuals > 3 > income Statement > dividends Per Share
0
Annuals > 3 > income Statement > shares Outstanding
79542627
Annuals > 3 > income Statement > income Tax Expense
13658000
Annuals > 3 > income Statement > EBITDA
-43229000
Annuals > 3 > income Statement > operating Margin
-394.8563408190225
Annuals > 3 > income Statement > total Other Income Expense Net
2347000
Annuals > 3 > income Statement > currency_symbol
EUR
Annuals > 3 > balance Sheet > cash
103756000
Annuals > 3 > balance Sheet > short Term Investments
16080000
Annuals > 3 > balance Sheet > receivables
1660000
Annuals > 3 > balance Sheet > inventories
-4946000
Annuals > 3 > balance Sheet > total Current Assets
138256000
Annuals > 3 > balance Sheet > property Plant Equipment
10174000
Annuals > 3 > balance Sheet > total Assets
267496000
Annuals > 3 > balance Sheet > payables
14729000
Annuals > 3 > balance Sheet > short Term Debt
30748000
Annuals > 3 > balance Sheet > long Term Debt
13503000
Annuals > 3 > balance Sheet > total Liabilities
160056000
Annuals > 3 > balance Sheet > equity
107440000
Annuals > 3 > balance Sheet > currency_symbol
EUR
Annuals > 3 > cash Flow > net Income
-52809000
Annuals > 3 > cash Flow > depreciation
4596000
Annuals > 3 > cash Flow > change In Working Capital
-9884000
Annuals > 3 > cash Flow > cash From Operations
-58457000
Annuals > 3 > cash Flow > capital Expenditures
1330000
Annuals > 3 > cash Flow > cash From Investing
-917000
Annuals > 3 > cash Flow > cash From Financing
26818000
Annuals > 3 > cash Flow > net Change In Cash
-33036000
Annuals > 3 > cash Flow > currency_symbol
EUR
Annuals > 3 > ratios > PE
-0.6639081708981022
Annuals > 3 > ratios > PB
1.3474272258004467
Annuals > 3 > ratios > ROE
-49.15208488458674
Annuals > 3 > ratios > ROA
-19.741977450130097
Annuals > 3 > ratios > FCF
-59787000
Annuals > 3 > ratios > Piotroski FScore
1
Annuals > 3 > ratios > fcf Percent
-4.936178996036988
Annuals > 3 > health Score
25
Valuation > metrics > PE
-0.2455112725665711
Valuation > metrics > PB
30.17273093089036
Valuation > final Score
20
Valuation > verdict
905.8% Overvalued
Profitability > metrics > ROE
-414.9300155520995
Profitability > metrics > ROA
-32.848041380898785
Profitability > metrics > Net Margin
-4.391769547325103
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
17.067068429237946
Risk > metrics > Interest Coverage
-6.840731772935163
Risk > final Score
-21
Risk > verdict
High
Liquidity > metrics > Current Ratio
4.818539043381535
Liquidity > metrics > Quick Ratio
4.818539043381535
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
20
Prev Valuations > 1
29.860591618384493
Prev Valuations > 2
80
Prev Profitabilities > 0
0
Prev Profitabilities > 1
0
Prev Profitabilities > 2
0
Prev Risks > 0
-2966
Prev Risks > 1
-169
Prev Risks > 2
8
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T22:02:38.379Z
Earnings History > 0 > period
2025-12-31
Earnings History > 0 > report Date
2026-03-26
Earnings History > 0 > date
2025-12-31
Earnings History > 0 > before After Market
BeforeMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
-0.14
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2025-09-30
Earnings History > 1 > report Date
2025-11-13
Earnings History > 1 > date
2025-09-30
Earnings History > 1 > before After Market
BeforeMarket
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-0.1422
Earnings History > 1 > eps Estimate
-0.14
Earnings History > 1 > eps Difference
-0.0022
Earnings History > 1 > surprise Percent
-1.5714
Earnings History > 2 > period
2025-06-30
Earnings History > 2 > report Date
2025-09-17
Earnings History > 2 > date
2025-06-30
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-0.2963
Earnings History > 2 > eps Estimate
-
Earnings History > 2 > eps Difference
0
Earnings History > 2 > surprise Percent
-
Earnings History > 3 > period
2025-03-31
Earnings History > 3 > report Date
2025-04-30
Earnings History > 3 > date
2025-03-31
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
-
Earnings History > 3 > eps Actual
-0.3
Earnings History > 3 > eps Estimate
-0.4
Earnings History > 3 > eps Difference
0.1
Earnings History > 3 > surprise Percent
25
Earnings History > 4 > period
2024-12-31
Earnings History > 4 > report Date
2025-03-27
Earnings History > 4 > date
2024-12-31
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
-
Earnings History > 4 > eps Actual
-0.3
Earnings History > 4 > eps Estimate
-0.4
Earnings History > 4 > eps Difference
0.1
Earnings History > 4 > surprise Percent
25
Earnings History > 5 > period
2024-09-30
Earnings History > 5 > report Date
2024-11-13
Earnings History > 5 > date
2024-09-30
Earnings History > 5 > before After Market
-
Earnings History > 5 > currency
-
Earnings History > 5 > eps Actual
0
Earnings History > 5 > eps Estimate
0
Earnings History > 5 > eps Difference
0
Earnings History > 5 > surprise Percent
-
Earnings History > 6 > period
2024-06-30
Earnings History > 6 > report Date
2024-09-12
Earnings History > 6 > date
2024-06-30
Earnings History > 6 > before After Market
-
Earnings History > 6 > currency
-
Earnings History > 6 > eps Actual
0
Earnings History > 6 > eps Estimate
-0.38
Earnings History > 6 > eps Difference
0.38
Earnings History > 6 > surprise Percent
100
Earnings History > 7 > period
2024-03-31
Earnings History > 7 > report Date
2024-05-14
Earnings History > 7 > date
2024-03-31
Earnings History > 7 > before After Market
BeforeMarket
Earnings History > 7 > currency
EUR
Earnings History > 7 > eps Actual
0
Earnings History > 7 > eps Estimate
0
Earnings History > 7 > eps Difference
0
Earnings History > 7 > surprise Percent
-
Earnings History > 8 > period
2023-12-31
Earnings History > 8 > report Date
2024-03-21
Earnings History > 8 > date
2023-12-31
Earnings History > 8 > before After Market
BeforeMarket
Earnings History > 8 > currency
EUR
Earnings History > 8 > eps Actual
0
Earnings History > 8 > eps Estimate
-0.41
Earnings History > 8 > eps Difference
0.41
Earnings History > 8 > surprise Percent
100
Earnings History > 9 > period
2023-09-30
Earnings History > 9 > report Date
2023-11-14
Earnings History > 9 > date
2023-09-30
Earnings History > 9 > before After Market
-
Earnings History > 9 > currency
EUR
Earnings History > 9 > eps Actual
0
Earnings History > 9 > eps Estimate
0
Earnings History > 9 > eps Difference
0
Earnings History > 9 > surprise Percent
-
Earnings History > 10 > period
2023-06-30
Earnings History > 10 > report Date
2023-09-14
Earnings History > 10 > date
2023-06-30
Earnings History > 10 > before After Market
-
Earnings History > 10 > currency
EUR
Earnings History > 10 > eps Actual
0.02
Earnings History > 10 > eps Estimate
-0.14
Earnings History > 10 > eps Difference
0.16
Earnings History > 10 > surprise Percent
114.2857
Earnings History > 11 > period
2023-03-31
Earnings History > 11 > report Date
2023-05-10
Earnings History > 11 > date
2023-03-31
Earnings History > 11 > before After Market
-
Earnings History > 11 > currency
EUR
Earnings History > 11 > eps Actual
0
Earnings History > 11 > eps Estimate
0
Earnings History > 11 > eps Difference
0
Earnings History > 11 > surprise Percent
-
Earnings History > 12 > period
2022-12-31
Earnings History > 12 > report Date
2023-03-23
Earnings History > 12 > date
2022-12-31
Earnings History > 12 > before After Market
-
Earnings History > 12 > currency
EUR
Earnings History > 12 > eps Actual
0
Earnings History > 12 > eps Estimate
-0.39
Earnings History > 12 > eps Difference
0.39
Earnings History > 12 > surprise Percent
100
Earnings History > 13 > period
2022-09-30
Earnings History > 13 > report Date
2022-11-14
Earnings History > 13 > date
2022-09-30
Earnings History > 13 > before After Market
-
Earnings History > 13 > currency
EUR
Earnings History > 13 > eps Actual
0
Earnings History > 13 > eps Estimate
0
Earnings History > 13 > eps Difference
0
Earnings History > 13 > surprise Percent
-
Earnings History > 14 > period
2022-06-30
Earnings History > 14 > report Date
2022-09-15
Earnings History > 14 > date
2022-06-30
Earnings History > 14 > before After Market
-
Earnings History > 14 > currency
EUR
Earnings History > 14 > eps Actual
0
Earnings History > 14 > eps Estimate
-0.08
Earnings History > 14 > eps Difference
0.08
Earnings History > 14 > surprise Percent
100
Earnings History > 15 > period
2022-03-31
Earnings History > 15 > report Date
2022-04-03
Earnings History > 15 > date
2022-03-31
Earnings History > 15 > before After Market
AfterMarket
Earnings History > 15 > currency
EUR
Earnings History > 15 > eps Actual
-0.16
Earnings History > 15 > eps Estimate
-0.17
Earnings History > 15 > eps Difference
0.01
Earnings History > 15 > surprise Percent
5.8824
Earnings History > 16 > period
2021-12-31
Earnings History > 16 > report Date
2022-03-24
Earnings History > 16 > date
2021-12-31
Earnings History > 16 > before After Market
-
Earnings History > 16 > currency
EUR
Earnings History > 16 > eps Actual
-0.66
Earnings History > 16 > eps Estimate
0
Earnings History > 16 > eps Difference
-0.66
Earnings History > 16 > surprise Percent
-
Earnings History > 17 > period
2021-09-30
Earnings History > 17 > report Date
2021-11-16
Earnings History > 17 > date
2021-09-30
Earnings History > 17 > before After Market
-
Earnings History > 17 > currency
EUR
Earnings History > 17 > eps Actual
0
Earnings History > 17 > eps Estimate
0
Earnings History > 17 > eps Difference
0
Earnings History > 17 > surprise Percent
-
Earnings History > 18 > period
2021-06-30
Earnings History > 18 > report Date
2021-09-15
Earnings History > 18 > date
2021-06-30
Earnings History > 18 > before After Market
-
Earnings History > 18 > currency
EUR
Earnings History > 18 > eps Actual
0
Earnings History > 18 > eps Estimate
0
Earnings History > 18 > eps Difference
0
Earnings History > 18 > surprise Percent
-
Earnings History > 19 > period
2021-03-31
Earnings History > 19 > report Date
2021-04-26
Earnings History > 19 > date
2021-03-31
Earnings History > 19 > before After Market
AfterMarket
Earnings History > 19 > currency
EUR
Earnings History > 19 > eps Actual
-0.18
Earnings History > 19 > eps Estimate
0.05
Earnings History > 19 > eps Difference
-0.23
Earnings History > 19 > surprise Percent
-460
Earnings History > 20 > period
2020-12-31
Earnings History > 20 > report Date
2021-03-18
Earnings History > 20 > date
2020-12-31
Earnings History > 20 > before After Market
BeforeMarket
Earnings History > 20 > currency
EUR
Earnings History > 20 > eps Actual
-0.176
Earnings History > 20 > eps Estimate
-0.09
Earnings History > 20 > eps Difference
-0.086
Earnings History > 20 > surprise Percent
-95.5556
Earnings History > 21 > period
2020-09-30
Earnings History > 21 > report Date
2020-11-17
Earnings History > 21 > date
2020-09-30
Earnings History > 21 > before After Market
BeforeMarket
Earnings History > 21 > currency
EUR
Earnings History > 21 > eps Actual
-0.0945
Earnings History > 21 > eps Estimate
-0.0945
Earnings History > 21 > eps Difference
0
Earnings History > 21 > surprise Percent
0
Earnings History > 22 > period
2020-06-30
Earnings History > 22 > report Date
2020-09-08
Earnings History > 22 > date
2020-06-30
Earnings History > 22 > before After Market
BeforeMarket
Earnings History > 22 > currency
EUR
Earnings History > 22 > eps Actual
-0.0827
Earnings History > 22 > eps Estimate
-0.08
Earnings History > 22 > eps Difference
-0.0027
Earnings History > 22 > surprise Percent
-3.375
Earnings History > 23 > period
2020-03-31
Earnings History > 23 > report Date
2020-05-12
Earnings History > 23 > date
2020-03-31
Earnings History > 23 > before After Market
BeforeMarket
Earnings History > 23 > currency
EUR
Earnings History > 23 > eps Actual
-0.0736
Earnings History > 23 > eps Estimate
0
Earnings History > 23 > eps Difference
-0.0736
Earnings History > 23 > surprise Percent
-
Earnings History > 24 > period
2019-12-31
Earnings History > 24 > report Date
2020-03-10
Earnings History > 24 > date
2019-12-31
Earnings History > 24 > before After Market
BeforeMarket
Earnings History > 24 > currency
EUR
Earnings History > 24 > eps Actual
-0.18
Earnings History > 24 > eps Estimate
-0.18
Earnings History > 24 > eps Difference
0
Earnings History > 24 > surprise Percent
0
Earnings History > 25 > period
2019-09-30
Earnings History > 25 > report Date
2019-11-13
Earnings History > 25 > date
2019-09-30
Earnings History > 25 > before After Market
BeforeMarket
Earnings History > 25 > currency
EUR
Earnings History > 25 > eps Actual
0.0445
Earnings History > 25 > eps Estimate
-0.09
Earnings History > 25 > eps Difference
0.1345
Earnings History > 25 > surprise Percent
149.4444
Earnings History > 26 > period
2019-06-30
Earnings History > 26 > report Date
2019-09-13
Earnings History > 26 > date
2019-06-30
Earnings History > 26 > before After Market
BeforeMarket
Earnings History > 26 > currency
EUR
Earnings History > 26 > eps Actual
-0.0884
Earnings History > 26 > eps Estimate
-0.09
Earnings History > 26 > eps Difference
0.0016
Earnings History > 26 > surprise Percent
1.7778
Earnings History > 27 > period
2019-03-31
Earnings History > 27 > report Date
2019-05-15
Earnings History > 27 > date
2019-03-31
Earnings History > 27 > before After Market
BeforeMarket
Earnings History > 27 > currency
EUR
Earnings History > 27 > eps Actual
0
Earnings History > 27 > eps Estimate
0
Earnings History > 27 > eps Difference
0
Earnings History > 27 > surprise Percent
-
Earnings History > 28 > period
2018-09-30
Earnings History > 28 > report Date
2018-11-15
Earnings History > 28 > date
2018-09-30
Earnings History > 28 > before After Market
-
Earnings History > 28 > currency
EUR
Earnings History > 28 > eps Actual
0.0791
Earnings History > 28 > eps Estimate
0
Earnings History > 28 > eps Difference
0.0791
Earnings History > 28 > surprise Percent
-
Earnings History > 29 > period
2017-09-30
Earnings History > 29 > report Date
2017-11-15
Earnings History > 29 > date
2017-09-30
Earnings History > 29 > before After Market
-
Earnings History > 29 > currency
EUR
Earnings History > 29 > eps Actual
0
Earnings History > 29 > eps Estimate
0
Earnings History > 29 > eps Difference
0
Earnings History > 29 > surprise Percent
-
Earnings History > 30 > period
2017-03-31
Earnings History > 30 > report Date
2017-05-15
Earnings History > 30 > date
2017-03-31
Earnings History > 30 > before After Market
-
Earnings History > 30 > currency
EUR
Earnings History > 30 > eps Actual
0
Earnings History > 30 > eps Estimate
0
Earnings History > 30 > eps Difference
0
Earnings History > 30 > surprise Percent
-
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
Stock Price
$0.00
increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/APortfolio Update: Will Tanger Inc benefit from rising consumer demand - Earnings Risk Report & Capital Protection Trading Alerts baoquankhu1.vn
Read more →Should value investors consider Kestra Medical Technologies Ltd. - July 2025 Trade Ideas & Weekly High Return Forecasts bollywoodhelpline.com
Read more →Showing 2 of 10
(Last Updated 2025-06-30)
Rating:
BUY
Target Price:
$5.154
Analyst Picks
Strong Buy
1
Buy
1
Hold
1
Sell
0
Strong Sell
0
(Last Updated 2025-06-30)
Health Score
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.18% of the total shares of Innate Pharma
1.
Range Cancer Therapeutics ETF(0.0681%)
since
2025/04/30
2.
Morgan Stanley - Brokerage Accounts(0.0556%)
since
2025/06/30
3.
Citadel Advisors Llc(0.0289%)
since
2025/06/30
4.
Millennium Management LLC(0.0127%)
since
2025/06/30
5.
UBS Group AG(0.0065%)
since
2025/06/30
6.
GAMMA Investing LLC(0.0037%)
since
2025/06/30
7.
Rhumbline Advisers(0.0005%)
since
2025/06/30
8.
Barclays PLC(0.0003%)
since
2025/06/30
9.
Optiver Holding B.V.(0.0001%)
since
2025/06/30
10.
Principal Securities Inc(0%)
since
2025/06/30
11.
Tower Research Capital LLC(0%)
since
2025/06/30
12.
Exchange Traded Concepts, LLC(0%)
since
2025/06/30
13.
Steward Partners Investment Advisory, LLC(0%)
since
2025/03/31
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
-0.14
Date
2025-09-30
EPS Actual
-0.1422
EPS Estimate
-0.14
EPS Difference
-0.0022
Surprise Percent
-1.5714%
(Last Updated 2025-06-30)
(Last Updated 2025-06-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-06-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-06-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.